Loading clinical trials...
Loading clinical trials...
Observation on the Efficacy of Sublingual Immunotherapy With Dust Mite Allergen for Perennial Allergic Rhinitis and the Mechanism of Action on ILCs With ILC1s and ILC2s and ILC3s
Conditions
Interventions
Dust mite drops (trade name: Changdi, Zhejiang Tawu Biotechnology Co. Ltd.).
Locations
1
China
Guangjun Tang
Anshan, Guizhou, China
Start Date
December 1, 2022
Primary Completion Date
December 31, 2023
Completion Date
December 30, 2024
Last Updated
October 6, 2022
NCT07419230
NCT06732414
NCT05494346
NCT07110311
NCT04815668
NCT06846385
Lead Sponsor
People's Hospital of Anshun City of Guizhou Province
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions